Purple Biotech Ltd - Asset Resilience Ratio

Latest as of September 2025: 2.21%

Purple Biotech Ltd (PPBT) has an Asset Resilience Ratio of 2.21% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Purple Biotech Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

ILA862.00K

≈ $2.31K USD Cash + Short-term Investments

Total Assets

ILA39.06 Million

≈ $104.72K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Purple Biotech Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Purple Biotech Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Purple Biotech Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Purple Biotech Ltd (PPBT) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA862.00K	2.21%
Total Liquid Assets	ILA862.00K	2.21%

Asset Resilience Insights

Limited Liquidity: Purple Biotech Ltd maintains only 2.21% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Purple Biotech Ltd Industry Peers by Asset Resilience Ratio

Compare Purple Biotech Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for Purple Biotech Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Purple Biotech Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	3.03%	ILA1.12 Million ≈ $3.01K	ILA37.04 Million ≈ $99.30K	+0.95pp
2023-12-31	2.08%	ILA923.00K ≈ $2.47K	ILA44.30 Million ≈ $118.77K	-29.19pp
2022-12-31	31.27%	ILA17.08 Million ≈ $45.80K	ILA54.62 Million ≈ $146.44K	-20.45pp
2021-12-31	51.73%	ILA36.31 Million ≈ $97.35K	ILA70.20 Million ≈ $188.20K	-3.83pp
2020-12-31	55.56%	ILA46.56 Million ≈ $124.82K	ILA83.80 Million ≈ $224.67K	+41.90pp
2019-12-31	13.66%	ILA2.01 Million ≈ $5.39K	ILA14.72 Million ≈ $39.46K	+3.33pp
2018-12-31	10.33%	ILA1.52 Million ≈ $4.08K	ILA14.72 Million ≈ $39.47K	--

pp = percentage points

About Purple Biotech Ltd

TA:PPBT Israel Biotechnology

Market Cap

$4.84 Million

ILA1.81 Billion ILA

Market Cap Rank

#28565 Global

#416 in Israel

Share Price

ILA1.00

Change (1 day)

+0.00%

52-Week Range

ILA1.00 - ILA4.70

All Time High

ILA3676.00